Randomized study of sertraline and low‐dose amitriptyline in patients with Parkinson's disease and depression: Effect on quality of life
Identifieur interne : 001390 ( Main/Corpus ); précédent : 001389; suivant : 001391Randomized study of sertraline and low‐dose amitriptyline in patients with Parkinson's disease and depression: Effect on quality of life
Auteurs : Angelo Antonini ; Silvana Tesei ; Anna Zecchinelli ; Paolo Barone ; Danilo De Gaspari ; Margherita Canesi ; Giorgio Sacilotto ; Nicoletta Meucci ; Claudio Mariani ; Gianni PezzoliSource :
- Movement Disorders [ 0885-3185 ] ; 2006-08.
English descriptors
- KwdEn :
Abstract
We assessed the effect of 3‐month treatment of sertraline (50 mg) or low‐dose amitriptyline (25 mg) on depression and quality of life in 31 patients with Parkinson's disease in a prospective single‐blind randomized study. Both drugs significantly reduced the Hamilton Depression Rating Scale (HDRS‐17) score. Completion rate was 75% for sertraline (12 of 16) and 73% for amitriptyline (11 of 15). Responder rate (HDRS‐17 score reduction ≥ 50%) was 83.3% for sertraline and 72.7% for amitriptyline. Sertraline but not amitriptyline treatment determined a significant benefit on quality of life (PDQ‐39 scale). We found no change in Unified Parkinson's Disease Rating Scale scores. However, the improvement in specific PDQ‐39 subscores (mobility, activities of daily living, and stigma) suggests that depression affects patient self‐perception of motor function and further emphasizes the need for its treatment. © 2006 Movement Disorder Society
Url:
DOI: 10.1002/mds.20895
Links to Exploration step
ISTEX:5B0CBB97DCBCF16FC36AD9B6CF78CC887277ADE2Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Randomized study of sertraline and low‐dose amitriptyline in patients with Parkinson's disease and depression: Effect on quality of life</title><author><name sortKey="Antonini, Angelo" sort="Antonini, Angelo" uniqKey="Antonini A" first="Angelo" last="Antonini">Angelo Antonini</name><affiliation><mods:affiliation>Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy</mods:affiliation></affiliation></author><author><name sortKey="Tesei, Silvana" sort="Tesei, Silvana" uniqKey="Tesei S" first="Silvana" last="Tesei">Silvana Tesei</name><affiliation><mods:affiliation>Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy</mods:affiliation></affiliation></author><author><name sortKey="Zecchinelli, Anna" sort="Zecchinelli, Anna" uniqKey="Zecchinelli A" first="Anna" last="Zecchinelli">Anna Zecchinelli</name><affiliation><mods:affiliation>Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy</mods:affiliation></affiliation></author><author><name sortKey="Barone, Paolo" sort="Barone, Paolo" uniqKey="Barone P" first="Paolo" last="Barone">Paolo Barone</name><affiliation><mods:affiliation>Centro Parkinson, Dipartimento di Scienze Neurologiche, Università Federico II, Napoli, Italy</mods:affiliation></affiliation></author><author><name sortKey="De Gaspari, Danilo" sort="De Gaspari, Danilo" uniqKey="De Gaspari D" first="Danilo" last="De Gaspari">Danilo De Gaspari</name><affiliation><mods:affiliation>Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy</mods:affiliation></affiliation></author><author><name sortKey="Canesi, Margherita" sort="Canesi, Margherita" uniqKey="Canesi M" first="Margherita" last="Canesi">Margherita Canesi</name><affiliation><mods:affiliation>Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy</mods:affiliation></affiliation></author><author><name sortKey="Sacilotto, Giorgio" sort="Sacilotto, Giorgio" uniqKey="Sacilotto G" first="Giorgio" last="Sacilotto">Giorgio Sacilotto</name><affiliation><mods:affiliation>Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy</mods:affiliation></affiliation></author><author><name sortKey="Meucci, Nicoletta" sort="Meucci, Nicoletta" uniqKey="Meucci N" first="Nicoletta" last="Meucci">Nicoletta Meucci</name><affiliation><mods:affiliation>Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy</mods:affiliation></affiliation></author><author><name sortKey="Mariani, Claudio" sort="Mariani, Claudio" uniqKey="Mariani C" first="Claudio" last="Mariani">Claudio Mariani</name><affiliation><mods:affiliation>Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy</mods:affiliation></affiliation></author><author><name sortKey="Pezzoli, Gianni" sort="Pezzoli, Gianni" uniqKey="Pezzoli G" first="Gianni" last="Pezzoli">Gianni Pezzoli</name><affiliation><mods:affiliation>Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:5B0CBB97DCBCF16FC36AD9B6CF78CC887277ADE2</idno><date when="2006" year="2006">2006</date><idno type="doi">10.1002/mds.20895</idno><idno type="url">https://api.istex.fr/document/5B0CBB97DCBCF16FC36AD9B6CF78CC887277ADE2/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001390</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Randomized study of sertraline and low‐dose amitriptyline in patients with Parkinson's disease and depression: Effect on quality of life</title><author><name sortKey="Antonini, Angelo" sort="Antonini, Angelo" uniqKey="Antonini A" first="Angelo" last="Antonini">Angelo Antonini</name><affiliation><mods:affiliation>Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy</mods:affiliation></affiliation></author><author><name sortKey="Tesei, Silvana" sort="Tesei, Silvana" uniqKey="Tesei S" first="Silvana" last="Tesei">Silvana Tesei</name><affiliation><mods:affiliation>Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy</mods:affiliation></affiliation></author><author><name sortKey="Zecchinelli, Anna" sort="Zecchinelli, Anna" uniqKey="Zecchinelli A" first="Anna" last="Zecchinelli">Anna Zecchinelli</name><affiliation><mods:affiliation>Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy</mods:affiliation></affiliation></author><author><name sortKey="Barone, Paolo" sort="Barone, Paolo" uniqKey="Barone P" first="Paolo" last="Barone">Paolo Barone</name><affiliation><mods:affiliation>Centro Parkinson, Dipartimento di Scienze Neurologiche, Università Federico II, Napoli, Italy</mods:affiliation></affiliation></author><author><name sortKey="De Gaspari, Danilo" sort="De Gaspari, Danilo" uniqKey="De Gaspari D" first="Danilo" last="De Gaspari">Danilo De Gaspari</name><affiliation><mods:affiliation>Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy</mods:affiliation></affiliation></author><author><name sortKey="Canesi, Margherita" sort="Canesi, Margherita" uniqKey="Canesi M" first="Margherita" last="Canesi">Margherita Canesi</name><affiliation><mods:affiliation>Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy</mods:affiliation></affiliation></author><author><name sortKey="Sacilotto, Giorgio" sort="Sacilotto, Giorgio" uniqKey="Sacilotto G" first="Giorgio" last="Sacilotto">Giorgio Sacilotto</name><affiliation><mods:affiliation>Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy</mods:affiliation></affiliation></author><author><name sortKey="Meucci, Nicoletta" sort="Meucci, Nicoletta" uniqKey="Meucci N" first="Nicoletta" last="Meucci">Nicoletta Meucci</name><affiliation><mods:affiliation>Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy</mods:affiliation></affiliation></author><author><name sortKey="Mariani, Claudio" sort="Mariani, Claudio" uniqKey="Mariani C" first="Claudio" last="Mariani">Claudio Mariani</name><affiliation><mods:affiliation>Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy</mods:affiliation></affiliation></author><author><name sortKey="Pezzoli, Gianni" sort="Pezzoli, Gianni" uniqKey="Pezzoli G" first="Gianni" last="Pezzoli">Gianni Pezzoli</name><affiliation><mods:affiliation>Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2006-08">2006-08</date><biblScope unit="volume">21</biblScope><biblScope unit="issue">8</biblScope><biblScope unit="page" from="1119">1119</biblScope><biblScope unit="page" to="1122">1122</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">5B0CBB97DCBCF16FC36AD9B6CF78CC887277ADE2</idno><idno type="DOI">10.1002/mds.20895</idno><idno type="ArticleID">MDS20895</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>amitriptyline</term><term>depression</term><term>sertraline</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We assessed the effect of 3‐month treatment of sertraline (50 mg) or low‐dose amitriptyline (25 mg) on depression and quality of life in 31 patients with Parkinson's disease in a prospective single‐blind randomized study. Both drugs significantly reduced the Hamilton Depression Rating Scale (HDRS‐17) score. Completion rate was 75% for sertraline (12 of 16) and 73% for amitriptyline (11 of 15). Responder rate (HDRS‐17 score reduction ≥ 50%) was 83.3% for sertraline and 72.7% for amitriptyline. Sertraline but not amitriptyline treatment determined a significant benefit on quality of life (PDQ‐39 scale). We found no change in Unified Parkinson's Disease Rating Scale scores. However, the improvement in specific PDQ‐39 subscores (mobility, activities of daily living, and stigma) suggests that depression affects patient self‐perception of motor function and further emphasizes the need for its treatment. © 2006 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Angelo Antonini MD</name><affiliations><json:string>Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy</json:string></affiliations></json:item><json:item><name>Silvana Tesei MD</name><affiliations><json:string>Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy</json:string></affiliations></json:item><json:item><name>Anna Zecchinelli MD</name><affiliations><json:string>Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy</json:string></affiliations></json:item><json:item><name>Paolo Barone MD</name><affiliations><json:string>Centro Parkinson, Dipartimento di Scienze Neurologiche, Università Federico II, Napoli, Italy</json:string></affiliations></json:item><json:item><name>Danilo De Gaspari BSc</name><affiliations><json:string>Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy</json:string></affiliations></json:item><json:item><name>Margherita Canesi MD</name><affiliations><json:string>Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy</json:string></affiliations></json:item><json:item><name>Giorgio Sacilotto MD</name><affiliations><json:string>Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy</json:string></affiliations></json:item><json:item><name>Nicoletta Meucci MD</name><affiliations><json:string>Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy</json:string></affiliations></json:item><json:item><name>Claudio Mariani MD</name><affiliations><json:string>Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy</json:string></affiliations></json:item><json:item><name>Gianni Pezzoli MD</name><affiliations><json:string>Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>depression</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>sertraline</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>amitriptyline</value></json:item></subject><articleId><json:string>MDS20895</json:string></articleId><language><json:string>eng</json:string></language><abstract>We assessed the effect of 3‐month treatment of sertraline (50 mg) or low‐dose amitriptyline (25 mg) on depression and quality of life in 31 patients with Parkinson's disease in a prospective single‐blind randomized study. Both drugs significantly reduced the Hamilton Depression Rating Scale (HDRS‐17) score. Completion rate was 75% for sertraline (12 of 16) and 73% for amitriptyline (11 of 15). Responder rate (HDRS‐17 score reduction ≥ 50%) was 83.3% for sertraline and 72.7% for amitriptyline. Sertraline but not amitriptyline treatment determined a significant benefit on quality of life (PDQ‐39 scale). We found no change in Unified Parkinson's Disease Rating Scale scores. However, the improvement in specific PDQ‐39 subscores (mobility, activities of daily living, and stigma) suggests that depression affects patient self‐perception of motor function and further emphasizes the need for its treatment. © 2006 Movement Disorder Society</abstract><qualityIndicators><score>3.789</score><pdfVersion>1.3</pdfVersion><pdfPageSize>594 x 792 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>4</keywordCount><abstractCharCount>943</abstractCharCount><pdfWordCount>2133</pdfWordCount><pdfCharCount>13672</pdfCharCount><pdfPageCount>4</pdfPageCount><abstractWordCount>138</abstractWordCount></qualityIndicators><title>Randomized study of sertraline and low‐dose amitriptyline in patients with Parkinson's disease and depression: Effect on quality of life</title><genre><json:string>article</json:string></genre><host><volume>21</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>4</total><last>1122</last><first>1119</first></pages><issn><json:string>0885-3185</json:string></issn><issue>8</issue><subject><json:item><value>Research Article</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2006</publicationDate><copyrightDate>2006</copyrightDate><doi><json:string>10.1002/mds.20895</json:string></doi><id>5B0CBB97DCBCF16FC36AD9B6CF78CC887277ADE2</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/5B0CBB97DCBCF16FC36AD9B6CF78CC887277ADE2/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/5B0CBB97DCBCF16FC36AD9B6CF78CC887277ADE2/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/5B0CBB97DCBCF16FC36AD9B6CF78CC887277ADE2/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Randomized study of sertraline and low‐dose amitriptyline in patients with Parkinson's disease and depression: Effect on quality of life</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>2006</date></publicationStmt><notesStmt><note>Pfizer, Inc.</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Randomized study of sertraline and low‐dose amitriptyline in patients with Parkinson's disease and depression: Effect on quality of life</title><author><persName><forename type="first">Angelo</forename><surname>Antonini</surname></persName><roleName type="degree">MD</roleName><note type="correspondence"><p>Correspondence: Parkinson Institute, Instituti Clinici di Perfezionamento, Via Bignami 1, 20126, Milano, Italy</p></note><affiliation>Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy</affiliation></author><author><persName><forename type="first">Silvana</forename><surname>Tesei</surname></persName><roleName type="degree">MD</roleName><affiliation>Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy</affiliation></author><author><persName><forename type="first">Anna</forename><surname>Zecchinelli</surname></persName><roleName type="degree">MD</roleName><affiliation>Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy</affiliation></author><author><persName><forename type="first">Paolo</forename><surname>Barone</surname></persName><roleName type="degree">MD</roleName><affiliation>Centro Parkinson, Dipartimento di Scienze Neurologiche, Università Federico II, Napoli, Italy</affiliation></author><author><persName><forename type="first">Danilo</forename><surname>De Gaspari</surname></persName><roleName type="degree">BSc</roleName><affiliation>Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy</affiliation></author><author><persName><forename type="first">Margherita</forename><surname>Canesi</surname></persName><roleName type="degree">MD</roleName><affiliation>Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy</affiliation></author><author><persName><forename type="first">Giorgio</forename><surname>Sacilotto</surname></persName><roleName type="degree">MD</roleName><affiliation>Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy</affiliation></author><author><persName><forename type="first">Nicoletta</forename><surname>Meucci</surname></persName><roleName type="degree">MD</roleName><affiliation>Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy</affiliation></author><author><persName><forename type="first">Claudio</forename><surname>Mariani</surname></persName><roleName type="degree">MD</roleName><affiliation>Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy</affiliation></author><author><persName><forename type="first">Gianni</forename><surname>Pezzoli</surname></persName><roleName type="degree">MD</roleName><affiliation>Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2006-08"></date><biblScope unit="volume">21</biblScope><biblScope unit="issue">8</biblScope><biblScope unit="page" from="1119">1119</biblScope><biblScope unit="page" to="1122">1122</biblScope></imprint></monogr><idno type="istex">5B0CBB97DCBCF16FC36AD9B6CF78CC887277ADE2</idno><idno type="DOI">10.1002/mds.20895</idno><idno type="ArticleID">MDS20895</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2006</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>We assessed the effect of 3‐month treatment of sertraline (50 mg) or low‐dose amitriptyline (25 mg) on depression and quality of life in 31 patients with Parkinson's disease in a prospective single‐blind randomized study. Both drugs significantly reduced the Hamilton Depression Rating Scale (HDRS‐17) score. Completion rate was 75% for sertraline (12 of 16) and 73% for amitriptyline (11 of 15). Responder rate (HDRS‐17 score reduction ≥ 50%) was 83.3% for sertraline and 72.7% for amitriptyline. Sertraline but not amitriptyline treatment determined a significant benefit on quality of life (PDQ‐39 scale). We found no change in Unified Parkinson's Disease Rating Scale scores. However, the improvement in specific PDQ‐39 subscores (mobility, activities of daily living, and stigma) suggests that depression affects patient self‐perception of motor function and further emphasizes the need for its treatment. © 2006 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Parkinson's disease</term></item><item><term>depression</term></item><item><term>sertraline</term></item><item><term>amitriptyline</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Research Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2005-08-23">Received</change><change when="2005-11-19">Registration</change><change when="2006-08">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/5B0CBB97DCBCF16FC36AD9B6CF78CC887277ADE2/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="80"><doi origin="wiley" registered="yes">10.1002/mds.v21:8</doi><numberingGroup><numbering type="journalVolume" number="21">21</numbering><numbering type="journalIssue">8</numbering></numberingGroup><coverDate startDate="2006-08">August 2006</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="110" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.20895</doi><idGroup><id type="unit" value="MDS20895"></id></idGroup><countGroup><count type="pageTotal" number="4"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Research Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 2006 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2005-08-23"></event><event type="manuscriptRevised" date="2005-10-25"></event><event type="manuscriptAccepted" date="2005-11-19"></event><event type="publishedOnlineEarlyUnpaginated" date="2006-04-24"></event><event type="firstOnline" date="2006-04-24"></event><event type="publishedOnlineFinalForm" date="2006-08-22"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:FullText result:FullText" date="2010-03-09"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">1119</numbering><numbering type="pageLast">1122</numbering></numberingGroup><correspondenceTo>Parkinson Institute, Instituti Clinici di Perfezionamento, Via Bignami 1, 20126, Milano, Italy</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS20895.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="1"></count><count type="tableTotal" number="2"></count><count type="referenceTotal" number="17"></count><count type="wordTotal" number="2370"></count></countGroup><titleGroup><title type="main" xml:lang="en">Randomized study of sertraline and low‐dose amitriptyline in patients with Parkinson's disease and depression: Effect on quality of life</title><title type="short" xml:lang="en">Sertraline and Low‐Dose Amitriptyline in PD Patients</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Angelo</givenNames><familyName>Antonini</familyName><degrees>MD</degrees></personName><contactDetails><email>angelo3000@yahoo.com</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Silvana</givenNames><familyName>Tesei</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Anna</givenNames><familyName>Zecchinelli</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Paolo</givenNames><familyName>Barone</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Danilo</givenNames><familyName>De Gaspari</familyName><degrees>BSc</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Margherita</givenNames><familyName>Canesi</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Giorgio</givenNames><familyName>Sacilotto</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au8" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Nicoletta</givenNames><familyName>Meucci</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au9" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Claudio</givenNames><familyName>Mariani</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au10" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Gianni</givenNames><familyName>Pezzoli</familyName><degrees>MD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="IT" type="organization"><unparsedAffiliation>Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="IT" type="organization"><unparsedAffiliation>Centro Parkinson, Dipartimento di Scienze Neurologiche, Università Federico II, Napoli, Italy</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Parkinson's disease</keyword><keyword xml:id="kwd2">depression</keyword><keyword xml:id="kwd3">sertraline</keyword><keyword xml:id="kwd4">amitriptyline</keyword></keywordGroup><fundingInfo><fundingAgency>Pfizer, Inc.</fundingAgency></fundingInfo><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>We assessed the effect of 3‐month treatment of sertraline (50 mg) or low‐dose amitriptyline (25 mg) on depression and quality of life in 31 patients with Parkinson's disease in a prospective single‐blind randomized study. Both drugs significantly reduced the Hamilton Depression Rating Scale (HDRS‐17) score. Completion rate was 75% for sertraline (12 of 16) and 73% for amitriptyline (11 of 15). Responder rate (HDRS‐17 score reduction ≥ 50%) was 83.3% for sertraline and 72.7% for amitriptyline. Sertraline but not amitriptyline treatment determined a significant benefit on quality of life (PDQ‐39 scale). We found no change in Unified Parkinson's Disease Rating Scale scores. However, the improvement in specific PDQ‐39 subscores (mobility, activities of daily living, and stigma) suggests that depression affects patient self‐perception of motor function and further emphasizes the need for its treatment. © 2006 Movement Disorder Society</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Randomized study of sertraline and low‐dose amitriptyline in patients with Parkinson's disease and depression: Effect on quality of life</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Sertraline and Low‐Dose Amitriptyline in PD Patients</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Randomized study of sertraline and low‐dose amitriptyline in patients with Parkinson's disease and depression: Effect on quality of life</title></titleInfo><name type="personal"><namePart type="given">Angelo</namePart><namePart type="family">Antonini</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy</affiliation><description>Correspondence: Parkinson Institute, Instituti Clinici di Perfezionamento, Via Bignami 1, 20126, Milano, Italy</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Silvana</namePart><namePart type="family">Tesei</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Anna</namePart><namePart type="family">Zecchinelli</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Paolo</namePart><namePart type="family">Barone</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Centro Parkinson, Dipartimento di Scienze Neurologiche, Università Federico II, Napoli, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Danilo</namePart><namePart type="family">De Gaspari</namePart><namePart type="termsOfAddress">BSc</namePart><affiliation>Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Margherita</namePart><namePart type="family">Canesi</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Giorgio</namePart><namePart type="family">Sacilotto</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Nicoletta</namePart><namePart type="family">Meucci</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Claudio</namePart><namePart type="family">Mariani</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Gianni</namePart><namePart type="family">Pezzoli</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2006-08</dateIssued><dateCaptured encoding="w3cdtf">2005-08-23</dateCaptured><dateValid encoding="w3cdtf">2005-11-19</dateValid><copyrightDate encoding="w3cdtf">2006</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">1</extent><extent unit="tables">2</extent><extent unit="references">17</extent><extent unit="words">2370</extent></physicalDescription><abstract lang="en">We assessed the effect of 3‐month treatment of sertraline (50 mg) or low‐dose amitriptyline (25 mg) on depression and quality of life in 31 patients with Parkinson's disease in a prospective single‐blind randomized study. Both drugs significantly reduced the Hamilton Depression Rating Scale (HDRS‐17) score. Completion rate was 75% for sertraline (12 of 16) and 73% for amitriptyline (11 of 15). Responder rate (HDRS‐17 score reduction ≥ 50%) was 83.3% for sertraline and 72.7% for amitriptyline. Sertraline but not amitriptyline treatment determined a significant benefit on quality of life (PDQ‐39 scale). We found no change in Unified Parkinson's Disease Rating Scale scores. However, the improvement in specific PDQ‐39 subscores (mobility, activities of daily living, and stigma) suggests that depression affects patient self‐perception of motor function and further emphasizes the need for its treatment. © 2006 Movement Disorder Society</abstract><note type="funding">Pfizer, Inc.</note><subject lang="en"><genre>Keywords</genre><topic>Parkinson's disease</topic><topic>depression</topic><topic>sertraline</topic><topic>amitriptyline</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><detail type="issue"><caption>no.</caption><number>8</number></detail><extent unit="pages"><start>1119</start><end>1122</end><total>4</total></extent></part></relatedItem><identifier type="istex">5B0CBB97DCBCF16FC36AD9B6CF78CC887277ADE2</identifier><identifier type="DOI">10.1002/mds.20895</identifier><identifier type="ArticleID">MDS20895</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2006 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001390 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001390 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:5B0CBB97DCBCF16FC36AD9B6CF78CC887277ADE2
|texte= Randomized study of sertraline and low‐dose amitriptyline in patients with Parkinson's disease and depression: Effect on quality of life
}}
| This area was generated with Dilib version V0.6.23. |  |